Concept Life Sciences Expands Into Alderley Park to Support Discovery Services Growth
News Sep 12, 2017
Image Credit: Concept Life Sciences
Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, recently announced it has expanded into new state-of-the-art laboratory space at Alderley Park in Cheshire, UK. The move supports the growth of the Company’s integrated discovery services business, adding capacity and bringing key disciplines together into one location.
The new laboratory space will increase Concept’s scientific capacity by over 30%, adding 75 FTEs to the company, including 55 scientists (medicinal chemists and biologists) over the two facilities, which total 12,400 square feet.
Concept’s drug discovery services encompass medicinal chemistry, pharmacology screening, assay development, and ADME, supporting biotech and pharma companies by adding value and IP to their small molecule discovery programmes. Adding capacity and co-locating these capabilities will further enable the Company to provide a truly integrated offering, spanning the discovery and development continuum.
“This significant investment will enable us to put in place the expertise to support Concept Life Sciences’ projected growth into 2018 and beyond,” said Michael Fort, Executive Chairman, Concept Life Sciences. “The expansion to the Mereside campus at Alderley Park is a pivotal step in the development of the group’s corporate and commercial profile to its international client base, opening new opportunities for collaboration and growth, markedly increasing the depth of our scientific offering and capitalising on Concept’s strong track record of delivery.”
“We welcome Concept to the Mereside campus, where the Company will benefit from the world class science facilities and access to talent. We are proud of the scientific ecosystem that exists here at Alderley Park and within the wider network of Manchester Science Partnerships, where we have close links with Universities, NHS institutions and research organisations,” commented Dr Chris Doherty, managing director at Alderley Park. “Concept Life Sciences’ track record shows a great deal of progress in a short space of time, and the new Alderley Park base will provide the laboratory and office infrastructure required to help maintain their recent momentum.”
This article has been republished from materials provided by Concept Life Sciences. Note: material may have been edited for length and content. For further information, please contact the cited source.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Allergy Amplifier Implicated in Asthma Also Intensifies Food AllergyNews
Scientist who previously reported that a small protein, aptly named histamine-releasing factor, played a pro-inflammatory role in asthma have now shown that it also serves as a “food allergy amplifier”. This work paves the way for blood tests to predict which patients will respond to allergy therapy, and strongly supports the idea that drugs designed to block HRF could prevent food allergy attacks.READ MORE
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE